everolimus / Generic mfg. - LARVOL DELTA

Non-Melanoma Skin Cancer Risk Among Transplant Patients: A Large Real-World Comparison of Immunosuppressive Regimens (AAD 2026) - "Recent reports suggest that azathioprine may increase the risk of NMSC compared with alternatives, but direct comparative evidence in large real-world populations remains limited.1-2 We conducted a retrospective analysis using the TriNetX Research Network, encompassing more than 275 million patients across 120 healthcare organizations...In contrast, no meaningful differences in NMSC incidence were found among cyclosporine, tacrolimus, sirolimus, or everolimus monotherapy, with comparable event rates and overlapping confidence intervals across all comparisons...For dermatologists involved in post-transplant care, recognizing how immunosuppressive selection influences NMSC burden is critical for tailoring surveillance, counseling, and interdisciplinary management. By integrating real-world data, this study provides practical evidence to guide both dermatologists and transplant clinicians in balancing graft preservation with skin cancer prevention in this high-risk population."

Clinical • Real-world • Real-world evidence • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Organ Transplantation • Solid Tumor • Transplantation

mTOR Inhibitors for Healthspan Extension: A Meta-analysis of Randomized Trials (AAD 2026) - "Oral rapamycin, everolimus, and RTB101 improved immune function, including enhanced vaccine responses (p = 0.001), reduced respiratory tract infections (p = 0.008), and upregulated interferon-stimulated gene expression (p < 10⁻⁵)... mTOR inhibitors improve immune and molecular aging markers with a neutral safety profile. Topical rapamycin demonstrates cutaneous rejuvenation, highlighting dermatologic applications of gerotherapeutics. Larger, biomarker-driven RCTs are needed to confirm long-term healthspan benefits."

Retrospective data • Infectious Disease • Respiratory Diseases

Real World Outcomes of Molecular Tumor Board Treatment Recommendations (HOPA 2026) - "Immunotherapy was the most commonly MTB level III recommended therapy patients received, followed by olaparib and everolimus. With a 5-15% published acceptance rate of MTB recommended therapies for all levels of evidence, the 12% implementation rate of level III recommendations identified at this single institution is high.1,2 In one study of 336 patients, approximately 8 patients received a level III recommendation and only two received these therapies.3 Outcomes were comparable to those reported in heavily pretreated solid tumor populations, with a median PFS of 2-3 and OS of 5-6 months is commonly reported.4,5,6 Our results reinforce the need for improved access to actionable therapies and development of effective therapies in this setting."

Clinical • Real-world • Real-world evidence • Oncology • Solid Tumor

Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment. (PubMed, Medicina (Kaunas)) - "Systemic therapies, including mTOR inhibitors (everolimus), anti-angiogenics (surufatinib), and peptide receptor radionuclide therapy (PRRT), extend survival in advanced cases, though immunotherapy efficacy remains limited. Future strategies emphasize molecular profiling, biomarker development, and multidisciplinary integration to optimize outcomes. This evolving paradigm prioritizes precision medicine, balancing oncologic control with quality of life and functional preservation."

IO biomarker • Journal • Review • Gastrointestinal Neuroendocrine Tumor • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Combination therapy • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Preclinical evidence for synergistic activity of alectinib and everolimus in ALK-positive non-small cell lung cancer (AACR 2026) - "Dual ALK and mTOR targeting with alectinib and everolimus produces synergistic antitumor activity in vitro and ex vivo, reflected by significantly increased apoptosis vs single agents. These findings support further investigation in in vivo models, including alectinib-sensitive and -resistant tumors.AI disclosure: AI was used for language editing only; content was verified by the authors."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CASP3 • CASP7 • MCL1

A comprehensive approach to targeting PI3K and Hippo pathways in sarcomas (AACR 2026) - "Cells were treated with MK2206 (Akt inhibitor), Everolimus (mTORC1 inhibitor), Romidepsin (HDAC inhibitor) and VT-107 (TEAD inhibitor) alone or in combination. TEAD inhibition disrupts TAZ/YAP transcriptional activity downstream, while HDAC inhibition restores Hippo signaling and suppresses TAZ/YAP transcription, and PI3K pathway inhibitors reduce survival signaling. These findings provide rationale for further investigation into dual-pathway inhibition as a therapeutic strategy, including mechanistic studies and in vivo validation to define therapeutic windows and potential clinical applications."

Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • LATS1 • MST1 • PTEN • TAFAZZIN

Machine learning accelerates discovery of synergistic- PI3K-mTOR combinations for robust tumor growth inhibition in KRAS G12 mutant patient-derived xenografts (AACR 2026) - "Notably, a key synergistic combination—involving Everolimus or Tacrolimus (mTORi) paired with Inavolisib (PI3Ki)—translated directly to significant therapeutic benefit in the PDX setting.These findings validate our PDX-informed strategy for rapidly identifying clinically relevant, synergistic combinations. The demonstrated efficacy of the Everolimus/Tacrolimus + Inavolisib combination provides compelling preclinical evidence, establishing this dual-agent approach as a strong therapeutic candidate for clinical evaluation in KRAS G12 mutant solid tumors."

Clinical • Machine learning • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Metastases • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment. (PubMed, Cancers (Basel)) - "Collectively, our findings suggest that the combination of DT2216/everolimus potentiates the anti-tumor efficacy of MRTX1133 associated with enhanced apoptosis induction and inhibition of compensatory survival signaling."

IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Targeted Protein Degradation • BCL2 • BCL2L1 • KRAS • PMAIP1

When Coverage Is Not Access: A Heart Transplant Recipient's Perspective on Everolimus, FDA Labeling, and the Problem of "Ghost Approval". (PubMed, J Heart Lung Transplant) - "This misalignment places patients at risk of treatment interruption and adverse outcomes. Greater alignment between regulatory frameworks, real-world clinical practice, and insurance policy is needed, along with stronger protections to ensure that coverage results in timely, reliable, and affordable access to life-sustaining medications."

FDA event • Journal • Transplantation

Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions-A Scoping Review. (PubMed, Curr Issues Mol Biol) - "VSs, particularly in NF2 patients, can cause significant morbidity and are often poorly managed by surgery or radiotherapy. Consequently, targeted medical therapies, especially anti-angiogenic agents, have emerged as valuable alternatives. Bevacizumab shows the most consistent benefits in tumor control, hearing stabilization, and quality of life, despite heterogeneous responses and notable toxicity. Evidence suggests that treatment discontinuation may lead to rapid tumor rebound, highlighting the need for long-term or maintenance strategies and careful monitoring. Future studies are needed to evaluate medical therapy integration with conventional treatments."

Journal • Review • Brain Cancer • Genetic Disorders • Neurofibromatosis • Oncology • Solid Tumor • NF1 • NF2

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. (PubMed, Cell Death Discov) - "Interestingly, A498-RAD10 cells were cross-resistant to cabozantinib, the tyrosine kinase inhibitor used in first-line treatment of mRCC with nivolumab...In silico data supported a context‑dependent role of PBRM1 in ccRCC patients. To the best of our knowledge, this is the first description of a mechanism of RAD001 and cabozantinib resistance through PBRM1 overexpression and CXCR7/CXCR4 downregulation and suggest new therapeutic perspective for cabozantinib-resistant patients."

Journal • Clear Cell Renal Cell Carcinoma • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • ACKR3 • CXCR4 • ERCC1 • PBRM1 • YY1

A phase 1 clinical trial of CT-01, a dual degrader of GSPT1 and NEK7, alone or in combination with everolimus for the treatment of hepatocellular carcinoma (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Combination therapy • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • GSPT1

mTOR inhibition augments antitumor immune response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment (AACR 2026) - "Treatment with the mTOR inhibitor Everolimus increased immune cell infiltration into the tumor through upregulated cytokine, chemokine activity, and enhanced chemokine receptor binding...Additionally, mTORi treatment interfered with PD-1/PD-L1 interaction between T cells and tumor cells by reducing PD-1 and PD-L1 expression, thereby augmenting T-cell cytotoxic function. These findings provide molecular evidence supporting mTORi as a promising therapeutic strategy for TP53-mutant, immune-cold, and immunotherapy-resistant HNSCC."

Biomarker • IO biomarker • Tumor microenvironment • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HIF1A • PD-1 • PD-L1 • TP53

Targeting NAMPT using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor (AACR 2026) - "RPT-E-037 synergized with pNETs standard of care mTOR targeted agent everolimus in both BON-1 and QGP-1 cell lines leading to superior cell deaths (CI<1). For the first time, this study reveals the therapeutic potential of RPT-E-037, a new NAMPT inhibitor, for pNETs in preclinical models. RPT-E-037 shows promise as a novel NAMPT inhibitor and deserves further clinical investigation for pNETs.Generative AI was used for improving the language of the abstract."

Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • NAMPT

Combinatorial screening reveals novel gene-drug synergies in breast cancer cells (AACR 2026) - "In MCF-7 cells, silencing R3HDM2 markedly increased sensitivity to CDK4/6 inhibitors, with fold-changes >8 for abemaciclib and >4 for palbociclib, implicating a critical role in cell cycle regulation...In T47D cells, knockdown of SLC25A12, DNAJC27, and DYNC1I2 genes sensitized cells to everolimus, docetaxel, and lapatinib (fold-change >14, >6, and >5). In MDA-MB-231 cells, knockdown of CEP192 and SLC25A12 genes significantly enhanced sensitivity to anastrozole and docetaxel (fold-change >7 and >4). Knockdown of several newly identified putative breast cancer susceptibility genes profoundly altered drug sensitivity in breast cancer cells, revealing mechanistic insights and potential drug targets for breast cancer. Knockdown of several newly identified putative breast cancer susceptibility genes profoundly altered drug sensitivity in breast cancer cells, revealing mechanistic insights and potential drug targets for breast cancer. Genes such as R3HDM2,..."

Breast Cancer • Oncology • Solid Tumor • DYNC1I2

When Low-Grade Endometrial Stromal Tumor Meets Uterine PEComa: Expanding the Morphologic, Genomic, and Transcriptomic Spectrum of TSC2-Mutant Neoplasms with Hybrid Features (USCAP 2026) - "Four received adjuvant therapy (letrozole, megace, everolimus); one later received everolimus after multiple recurrences but progressed. TSC2-mutant neoplasms with hybrid morphology generally resemble LGEST, often with an admixed epithelioid component, frequently express CD10, ER, and HMB-45, and most cluster with TSC2 wild-type LGEST. Given their TSC2 alterations, patients may be eligible for mTOR inhibitors, though response has been variable. Recognition of these hybrid tumors is important for accurate diagnosis, prognosis, and management."

Stroma • Endometrial Cancer • Oncology • Uterine Cancer • CALD • ER • JAZF1 • MLANA • MME • SUZ12 • TSC2

Short-term rapamycin treatment of an older human cohort alters immune and inflammatory markers but fails to re-set the epigenetic biological clock (IMMUNOLOGY 2026) - "Introduction/Rationale: Pharmacological inhibition of the mTOR pathway with rapamycin (RAPA) extends lifespan and improves aspects of healthspan in mice. Although many RAPA effects could be elicited by short-term inhibition of mTOR, other parameters will likely require a longer treatment. To explore this possibility, we were recently funded for a PK/PD analysis of mTOR inhibition in older humans. The goal is to identify the optimal drug (RAPA vs."

Inflammation • FOXP3 • ITGAM

Cardiac REDD1 alters glucose and fatty acid metabolic gene expression via an mTORC1-independent, PPARα-dependent mechanism and drives hypertrophic growth. (PubMed, bioRxiv) - "In order to determine if our observed effects were mTORC1-dependent, we utilized mTORC1-specific inhibitor, everolimus...We also outline a mechanism whereby REDD1 inhibits PPARα activity, thereby inhibiting the expression of its target genes, including PDK4 and those involved in fatty acid oxidation. Finally, we demonstrate that these effects are independent of REDD1's ability to inhibit mTORC1."

Journal • Diabetes • ACSL1 • PDK4 • PPARA

OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS WITH PERI-TRANSPLANT-RUXOLITINIB PROPHYLAXIS (EBMT 2026) - "Pre-alloHCT treatments included ruxolitinib (73.5%), hydroxyurea (42.6%) and supportive therapies (17.6%, e.g erythropoietin, anagrelide and phlebotomy). All patients received peripheral blood stem cell grafts, mostly from 10/10 matched unrelated donors (MUD, 67.7%) (Table 1) after conditioning with fludarabine, thiotepa and melphalan (FTM, 44.1%), fludarabine, carmustin and melphalan (FBM, 30.9%) or thiotepa, fludarabine and treosulfan (TFTreo, 25.0%). GvHD prophylaxis consisted of a backbone of cyclosporine A (CsA) + mycophenolate (MPA) in 85.3% or everolimus + MPA in 14.7% of patients and was combined with serotherapy (anti-T-lymphocyte globulin (ATLG) or alemtuzumab) in 80.9% of cases.Prevalence of GvHD requiring systemic treatment (acute GvHD (aGvHD) or chronic GvHD (cGvHD)) was 50.0% in the entire cohort (with ruxolitinib: 28.6%, without ruxolitinib: 55.6%) and distributed equally between aGvHD (overall: 36.8%, with ruxolitinib: 28.6%, without ruxolitinib: 35.2%)..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Transplantation • CALR • JAK2

OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS WITH PERI-TRANSPLANT-RUXOLITINIB PROPHYLAXIS (EBMT 2026) - "Pre-alloHCT treatments included ruxolitinib (73.5%), hydroxyurea (42.6%) and supportive therapies (17.6%, e.g erythropoietin, anagrelide and phlebotomy). All patients received peripheral blood stem cell grafts, mostly from 10/10 matched unrelated donors (MUD, 67.7%) (Table 1) after conditioning with fludarabine, thiotepa and melphalan (FTM, 44.1%), fludarabine, carmustin and melphalan (FBM, 30.9%) or thiotepa, fludarabine and treosulfan (TFTreo, 25.0%). GvHD prophylaxis consisted of a backbone of cyclosporine A (CsA) + mycophenolate (MPA) in 85.3% or everolimus + MPA in 14.7% of patients and was combined with serotherapy (anti-T-lymphocyte globulin (ATLG) or alemtuzumab) in 80.9% of cases.Prevalence of GvHD requiring systemic treatment (acute GvHD (aGvHD) or chronic GvHD (cGvHD)) was 50.0% in the entire cohort (with ruxolitinib: 28.6%, without ruxolitinib: 55.6%) and distributed equally between aGvHD (overall: 36.8%, with ruxolitinib: 28.6%, without ruxolitinib: 35.2%)..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Transplantation • CALR • JAK2

Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma. (PubMed, JCO Precis Oncol) - "The 15G score was independently prognostic in metastatic ccRCC among patients receiving different systemic therapy regimens."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Network meta-analysis of second- and later-line therapies in advanced renal cell carcinoma: A comparative effectiveness approach. (ASCO-GU 2026) - "Lenvatinib + everolimus (HR 0.49 vs placebo) and atezolizumab + cabozantinib (HR 0.56 vs placebo) demonstrated the greatest OS benefit. Compared with other active regimens, lenvatinib + everolimus significantly improved OS versus everolimus and temsirolimus monotherapy, ranking highest for OS (P-score = 0.88)...Lenvatinib + everolimus also ranked first for ORR (P-score = 0.94), followed by belzutifan (P-score = 0.86)... In this NMA, lenvatinib + everolimus demonstrated the greatest overall efficacy across OS, PFS, and ORR, outperforming all other therapies except telaglenastat + cabozantinib in PFS. These findings suggest lenvatinib + everolimus as the leading option for second- or later-line therapy in advanced RCC. However, results should be interpreted with caution and warrant confirmation in future large, head-to-head randomized trials."

HEOR • Metastases • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: Richard Stone, MD | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology